Status and Prospects for Psychopharmacology

  • Ross J. Baldessarini


Modern psychopharmacology has been evolving since the 1950s. Its contributions have been enormous and of fundamental importance to modern psychiatric therapeutics, encouraging and enabling the shift away from long-term institutional care, to brief inpatient interventions for crises, and reliance on ambulatory care. In addition, the clinical benefits provided by much of psychiatric chemotherapy, though typically incomplete, have stimulated decades of renewed efforts to develop a more biomedically based theoretical and academic psychiatry. In addition, the psychopharmaceutical industry has been especially successful in blending science and business to provide products of considerable social value.


Psychiatric Disorder Psychotropic Drug Academic Psychiatry Abrupt Discontinuation Psychotropic Medicine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    American Psychiatric Association. Diagnostic and statistical Manual of Mental disorders, fourth revision, text revision. Washington, MD: American Psychiatric Association; 2000.CrossRefGoogle Scholar
  2. 2.
    Angell M. The truth about the drug companies. New York: Random House; 2004.Google Scholar
  3. 3.
    Baldessarini RJ. American biological psychiatry and psychopharmacology 1944–1994, Chap. 16. In: Menninger RW, Nemiah JC, editors. American Psychiatry After World War II (1944–1994), a Volume Celebrating the 150th Anniversary of the Founding of the American Psychiatric Association. Washington DC: APA Press; 2000. p. 371–412.Google Scholar
  4. 4.
    Centorrino F, Cincotta SL, Talamo A, Fogarty KV, Guzzetta F, Saadeh MG, et al. Hospital use of antipsychotic drugs: polytherapy. Compr Psychiatry. 2008;49:65–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Centorrino F, Ventriglio A, Vincenti A, Talamo A, Baldessarini RJ. Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004. Hum Psychopharmacol. 2010;25:179–86.PubMedCrossRefGoogle Scholar
  6. 6.
    Chiesa A, Chierzi F, De Ronchi D, Serretti A. Quetiapine for bipolar depression: systematic review and meta-analysis. Int Clin Psychopharmacol. 2012;27:76–90.PubMedCrossRefGoogle Scholar
  7. 7.
    Conn PJ, Roth BL. Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings. Neuropsychopharmacology. 2008;33:2048–60.PubMedCrossRefGoogle Scholar
  8. 8.
    Cutler NR, Sramek JJ, Murphy MF, Riordan H, Biek P, Carta A. Critical pathways to success in CNS drug development. New York: Wiley; 2010.CrossRefGoogle Scholar
  9. 9.
    Eliot TS. The Rock. London: Faber & Faber Publishers; 1934.Google Scholar
  10. 10.
    Frye MA, Ketter TA, Leverich GS, Huggins T, Lantz C, Denicoff KD, et al. Increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry. 2000;61:9–15.PubMedCrossRefGoogle Scholar
  11. 11.
    Gearing RE, Townsend L, MacKenzie M, Charach A. Reconceptualizing medication adherence: six phases of dynamic adherence. Harv Rev Psychiatry. 2011;19:177–89.PubMedCrossRefGoogle Scholar
  12. 12.
    Harris G. Deal in place for inspecting foreign drugs. New York: New York Times; 13 August 2011.
  13. 13.
    Healy D. The Creation of Psychopharmacology. Cambridge, MA: Harvard University; 2002.Google Scholar
  14. 14.
    Ingersoll KS, Cohen J. Impact of medication regimen factors on adherence to chronic treatment: review of literature. J Behav Med. 2008;31:213–24.PubMedCrossRefGoogle Scholar
  15. 15.
    Khalsa HMK, Salvatore P, Hennen J, Tohen M, Baldessarini RJ. Suicidal events and accidents in 216 first-episode bipolar-I disorder patients: predictive factors. J Affect Disord. 2008;106:179–84.PubMedCrossRefGoogle Scholar
  16. 16.
    Lazare A, editor. Outpatient Psychiatry: Diagnosis and Treatment. 2nd ed. Philadelphia, PA: Lippincott-Williams & Wilkins; 1988.Google Scholar
  17. 17.
    Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: meta-analysis. Lancet. 2009;373:31–41.PubMedCrossRefGoogle Scholar
  18. 18.
    Lieberman JA. Psychiatric drug development: why so slow? 2010.
  19. 19.
    Marazziti D, Carlini M, Dell’osso L. Treatment strategies of obsessive-compulsive disorder and panic disorder/agoraphobia. Curr Top Med Chem. 2012;12:238–53.PubMedCrossRefGoogle Scholar
  20. 20.
  21. 21.
    Meyers M. Happy accidents: serendipity in modern medical breakthroughs. New York: Arcade Publishers; 2007.Google Scholar
  22. 22.
    Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010;67:26–36.PubMedCrossRefGoogle Scholar
  23. 23.
    Ösby U, Brandt L, Correia N, Ekbom A, Sparén P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844–50.PubMedCrossRefGoogle Scholar
  24. 24.
    Payne K, Gurwitz D, editors. The economics of drug discovery and development. Drug Dev Res. 2010;71(special issue):445–506.Google Scholar
  25. 25.
    Pope Jr HG, McElroy SL, Keck Jr PE, Hudson JI. Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry. 1991;48:62–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Rosen S, Baldessarini RJ. Acquisition costs of psychopharmacological agents (internal report). Belmont, MA: McLean Hospital Pharmacy Department; 2011.Google Scholar
  27. 27.
    Salvatore P, Baldessarini RJ, Tohen M, Khalsa HMK, Perez Sanchez-Toledo J, Zarate Jr CA, et al. McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry. 2009;70:458–66.PubMedCrossRefGoogle Scholar
  28. 28.
    Salvatore P, Baldessarini RJ, Tohen M, Khalsa HM, Sanchez-Toledo JP, Zarate Jr CA, et al. McLean-Harvard International First-Episode Project: two-year stability of ICD-10 diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry. 2011;72:183–93.PubMedCrossRefGoogle Scholar
  29. 29.
    Seo HJ, Chiesa A, Lee SJ, Patkar AA, Han C, Masand PS, et al. Safety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications. Clin Neuropharmacol. 2011;34:39–47.PubMedCrossRefGoogle Scholar
  30. 30.
    Simon GE, Perlis RH. Personalized medicine for depression: can we match patients with treatments? Am J Psychiatry. 2010;167:1445–55.PubMedCrossRefGoogle Scholar
  31. 31.
    Tohen M, Vieta E, Goodwin GM, Sun B, Amsterdam JD, Banov M, et al. Olanzapine versus divalproex vs. placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. J Clin Psychiatry. 2008;69:1776–89.PubMedCrossRefGoogle Scholar
  32. 32.
    Undurraga J, Baldessarini RJ. Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology. 2012;37:851–64.PubMedCrossRefGoogle Scholar
  33. 33.
    Williams M. Productivity shortfalls in drug discovery: contributions from the preclinical sciences? J Pharmacol Exp Ther. 2011;336:3–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. Size and burden of mental disorders and other disorders of the brain in Europe in 2010. Eur Neuropsychopharmacol. 2011;21:655–79.PubMedCrossRefGoogle Scholar
  35. 35.
    World Health Organization. International Classification of Diseases, tenth revision (ICD-10). Geneva: World Health Organization (WHO) 1994.Google Scholar
  36. 36.
    Yildiz A, Guleryuz S, Ankerst DP, Ongür D, Renshaw PF. Protein kinase C inhibition in the treatment of mania: double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry. 2008;65:255–63.PubMedCrossRefGoogle Scholar
  37. 37.
    Yildiz A, Vieta E, Leucht S, Baldessarini RJ. Efficacy of antimanic treatments; meta-analysis of randomized, controlled trials. Neuropsychopharmacology. 2011;36:375–89.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Ross J. Baldessarini
    • 1
  1. 1.Harvard Medical SchoolMcLean Hospital Psychopharmacology ProgramBelmontUSA

Personalised recommendations